Drug Development · global
Suppressing complement production in the liver: Phase 3 sefaxersen trial reduces proteinuria by 43% in IgA nephropathy
The antisense drug sefaxersen further reduced proteinuria in patients with IgA nephropathy on top of standard treatment. These interim Phase 3 results support its therapeutic potential, but whether it can preserve kidney function over the long term remains to be seen in follow-up data.
For patients with IgA nephropathy, protein loss in the urine is an important indicator for tracking kidney damage; the longer-term treatment goal is to preserve the kidneys’ filtering capacity. Roche and its subsidiary Genentech announced on October 23 that the investigational drug sefaxersen reduced proteinuria by 43.1% compared with placebo at week 37 in the Phase 3 IMAgINATION trial. This is a positive signal for treatment, while the trial continues to investigate whether kidney function can receive lasting protection.
These interim data were presented at the American Society of Nephrology (ASN) Kidney Week 2026. The study measured the primary efficacy outcome using the protein-to-creatinine ratio (UPCR) in 24-hour urine collections; the relative reduction of 43.1% between groups had a 95% confidence interval of 32.5% to 52.0%, with a P value below 0.0001. This represents a treatment effect relative to placebo and should not be interpreted as the same percentage reduction in proteinuria for every patient, nor as a 43.1% reduction in the risk of kidney failure.
IMAgINATION is a randomized, double-blind, placebo-controlled trial involving adults with primary IgA nephropathy at higher risk of disease progression, with both groups receiving optimized standard treatment. The companies reported total enrollment of 459 participants, assigned in a one-to-one ratio; medical news outlet HCPLive further distinguished a primary study population of 438 participants. According to that outlet, participants received subcutaneous injections on days 1, 15, and 29, followed by dosing every four weeks.
Sefaxersen targets the liver. This antisense oligonucleotide drug acts on RNA to reduce the production of complement factor B, with the aim of inhibiting the alternative complement pathway. In IgA nephropathy, immune complexes deposited in the kidneys can activate this pathway, driving inflammation and damage; the drug therefore seeks to intervene in one part of the immune response, rather than solely addressing protein loss in the urine.
According to the results released by Roche and Genentech, treatment effects were consistent in direction across prespecified subgroups; among patients with hematuria at baseline, a higher proportion in the sefaxersen group also achieved resolution of hematuria at week 37. However, the announcement did not provide specific percentages for this outcome, making it difficult to assess the magnitude of the benefit and its practical significance for different patients.
On safety, the companies said no new safety signals were identified and the overall profile was consistent with the earlier Phase 2 study. This description still has informational limits: the announcement did not provide complete data on adverse events, serious adverse events, or discontinuation rates, so the full risks of long-term treatment cannot be assessed solely from the statement that there were “no new signals.”
The next key question is whether the improvement in proteinuria will be accompanied by slower loss of kidney function. The trial will remain blinded and assess changes in kidney function, measured by estimated glomerular filtration rate (eGFR), at week 105. Roche and Genentech plan to share the data with health authorities but have not provided a timeline for submitting an application for marketing approval; the current results also do not yet demonstrate that this treatment can delay dialysis or kidney transplantation.